麝香保心丸、复方丹参滴丸与脑心通胶囊治疗冠心病稳定型心绞痛的药物经济学评价

王晓丽; 董占军; 张慧玲; 袁耀辉; 种宝贵; 刘国强

doi:10.14009/j.issn.1672-2124.2023.02.021

您当前的位置：

首页 >

文章列表页 >

麝香保心丸、复方丹参滴丸与脑心通胶囊治疗冠心病稳定型心绞痛的药物经济学评价

用药评价 | 更新时间：2023-04-14

- 麝香保心丸、复方丹参滴丸与脑心通胶囊治疗冠心病稳定型心绞痛的药物经济学评价
- Pharmacoecomic Evaluation on Shexiang Baoxin Pills, Compound Danshen Dropping Pills and Naoxintong Capsules in the Treatment of Stable Angina Pectoris of Coronary Heart Disease
- 中国医院用药评价与分析 2023年第2期页码：230-233
- 作者机构：
  
  1. 河北医科大学第三医院药剂科
  2. 河北省人民医院药学部
  3. 河北医科大学第三医院中医科
  4. 邢台市第三医院药剂科
  5. 哈励逊国际和平医院药剂科
- 作者简介：
- 基金信息：
  
  河北省自然科学基金项目（No.H2021206407）
- DOI：10.14009/j.issn.1672-2124.2023.02.021
  中图分类号： R259
- 纸质出版日期：2023，
扫描看全文
王晓丽, 董占军, 张慧玲, 等. 麝香保心丸、复方丹参滴丸与脑心通胶囊治疗冠心病稳定型心绞痛的药物经济学评价[J]. 中国医院用药评价与分析, 2023,(2):230-233.

WANG Xiaoli, DONG Zhanjun, ZHANG Huiling, et al. Pharmacoecomic Evaluation on Shexiang Baoxin Pills, Compound Danshen Dropping Pills and Naoxintong Capsules in the Treatment of Stable Angina Pectoris of Coronary Heart Disease[J]. 2023,(2):230-233.
王晓丽, 董占军, 张慧玲, 等. 麝香保心丸、复方丹参滴丸与脑心通胶囊治疗冠心病稳定型心绞痛的药物经济学评价[J]. 中国医院用药评价与分析, 2023,(2):230-233. DOI： 10.14009/j.issn.1672-2124.2023.02.021.

WANG Xiaoli, DONG Zhanjun, ZHANG Huiling, et al. Pharmacoecomic Evaluation on Shexiang Baoxin Pills, Compound Danshen Dropping Pills and Naoxintong Capsules in the Treatment of Stable Angina Pectoris of Coronary Heart Disease[J]. 2023,(2):230-233. DOI： 10.14009/j.issn.1672-2124.2023.02.021.

摘要

目的：评价麝香保心丸、复方丹参滴丸与脑心通胶囊治疗冠心病稳定型心绞痛的经济性。方法：从卫生体系角度出发，构建决策树模型，采用成本-效用分析，对麝香保心丸、复方丹参滴丸与脑心通胶囊治疗冠心病稳定型心绞痛进行药物经济学评价。结果：与麝香保心丸组比较，脑心通胶囊组方案的增量成本-效用比为3 501 593.41

＞3倍人均GDP

麝香保心丸组方案更具有经济性；与复方丹参滴丸组比较，麝香保心丸组方案的成本更低，效果更好；因此，麝香保心丸组方案最具有经济性。敏感性分析显示结果具有稳健性。结论：与复方丹参滴丸、脑心通胶囊比较，麝香保心丸治疗冠心病稳定型心绞痛更具有药物经济学优势。

Abstract

OBJECTIVE: To evaluate the economical efficiency of Shexiang Baoxin pills

compound Danshen dropping pills and Naoxintong capsules in the treatment of stable angina pectoris of coronary heart disease. METHODS: Based on the perspective of health system

a decision tree model was constructed

and cost-utility analysis was used to conduct pharmacoeconomic evaluation on Shexiang Baoxin pills

compound Danshen dripping pills and Naoxintong capsules in the treatment of stable angina pectoris of coronary heart disease. RESULTS: Compared with the Shexiang Baoxin pills group

the incremental cost-utility ratio of the Naoxintong capsules group regimen was 3 501 593.41

which was greater than 3 times the GDP per capita

so that the Shexiang Baoxin pills group regimen was more economical; compared with the compound Danshin dropping pills group

the Shexiang Baoxin pills group regimen was less costly and more effective; therefore

the Shexiang Baoxin pills group regimen was the most economical. Sensitivity analysis showed that the results were robust. CONCLUSIONS: Compared with compound Danshin dropping pills and Naoxintong capsules

the Shexiang Baoxin pills has more pharmacoeconomic advantages in the treatment of stable angina pectoris in coronary heart disease.

关键词

麝香保心丸复方丹参滴丸脑心通胶囊冠心病稳定型心绞痛

Keywords

Shexiang Baoxin pillsCompound Danshen dripping pillsNaoxintong capsulesStable angina pectoris of coronary heart disease

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

麝香保心丸与复方丹参滴丸治疗冠心病心绞痛的循证药物经济学评价

麝香保心丸联合伊伐布雷定治疗慢性心力衰竭合并慢性阻塞性肺疾病的临床研究

复方丹参滴丸与麝香保心丸分别治疗不稳定型心绞痛的药物经济学评价

麝香保心丸治疗冠心病心绞痛有效性和安全性的系统评价